Skip to main content

Table 3 Segmented regression analysis for vascular protective medication and comparator coverage 2010 to 2016, EMR cohort

From: Impact of the diabetes Canada guideline dissemination strategy on dispensed vascular protective medications for older patients in Ontario, Canada: a linked EMR and administrative data study

Statin
VariableEstimateSEPvalue
Baseline prescription rate63.260.52<.0001
Pre-intervention slope0.110.060.11
Change at guideline (2013Q2)− 0.900.610.15
Slope change−0.030.090.70
ACEi or ARB
 Baseline prescription rate63.990.43<.0001
 Pre-intervention slope−0.150.050.01
 Change at guideline (2013Q2)−0.460.510.38
 Slope change0.030.070.64
Antiplatelet
 Baseline prescription rate9.540.15<.0001
 Pre-intervention slope−0.120.02<.0001
 Change at guideline (2013Q2)0.130.170.5
 Slope change0.0010.030.97
PPI
 Baseline prescription rate21.840.44<.0001
 Pre-intervention slope0.230.05<.0001
 Change at guideline (2013Q2)0.270.430.54
 Slope change−0.070.080.36
  1. SE standard error
  2. ACEi angiotensin-converting enzyme inhibitor; ARB angiotensin receptor blockers; PPI proton pump inhibitor